Meropenem Kabi meropenem (as trihydrate) 1 g Powder for Injection Vials Australia - inglese - Department of Health (Therapeutic Goods Administration)

meropenem kabi meropenem (as trihydrate) 1 g powder for injection vials

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

Meropenem Kabi meropenem (as trihydrate) 500 mg Powder for Injection Vials Australia - inglese - Department of Health (Therapeutic Goods Administration)

meropenem kabi meropenem (as trihydrate) 500 mg powder for injection vials

fresenius kabi australia pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - indications,meropenem kabi is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics:,? community acquired lower respiratory tract infection ,? hospital acquired lower respiratory tract infection,? complicated urinary tract infection,? febrile neutropaenia,? intra-abdominal and gynaecological (poly microbial) infections,? complicated skin and skin structure infections,? meningitis,? septicaemia

NOCUTIL Nasal Spray Solution 0.1 Mg/Ml Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil nasal spray solution 0.1 mg/ml

gebro pharma gmbh - desmopressin acetate - nasal spray solution - 0.1 mg/ml

NOCUTIL 0.1 MG TABLETS Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil 0.1 mg tablets

gebro pharma gmbh - desmopressin acetate - tablets - 0.1 milligram

NOCUTIL 0.2 MG TABLETS Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil 0.2 mg tablets

gebro pharma gmbh - desmopressin acetate - tablets - 0.2 milligram

NEULASTIM Israele - inglese - Ministry of Health

neulastim

amgen europe b.v. - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml ml - pegfilgrastim - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

NOCUTIL 0.1 Mg/Ml Nasal Spray Solution Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil 0.1 mg/ml nasal spray solution

gebro pharma gmbh - desmopressin acetate - nasal spray solution - 0.1 mg/ml

NOCUTIL 0.1 MG TABLETS 0.1 Milligram Tablets Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil 0.1 mg tablets 0.1 milligram tablets

gebro pharma gmbh - desmopressin acetate - tablets - 0.1 milligram

NOCUTIL 0.2 MG TABLETS 0.2 Milligram Tablets Irlanda - inglese - HPRA (Health Products Regulatory Authority)

nocutil 0.2 mg tablets 0.2 milligram tablets

gebro pharma gmbh - desmopressin acetate - tablets - 0.2 milligram

Lonquex Unione Europea - inglese - EMA (European Medicines Agency)

lonquex

teva b.v. - lipegfilgrastim - neutropenia - immunostimulants, , colony stimulating factors - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).